S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
NYSE:AGE

AgeX Therapeutics (AGE) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
$0.22
$16.51
52-Week Range
N/A
Volume
3,753 shs
Average Volume
9,164 shs
Market Capitalization
$11.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AGE stock logo

About AgeX Therapeutics Stock (NYSE:AGE)

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.

AGE Stock News Headlines

Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
AgeX Therapeutics Inc AGE
25 States with the Highest Life Expectancy in the US
See More Headlines
Receive AGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AgeX Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Employees
5
Year Founded
N/A

Profitability

Net Income
$-14,800,000.00
Net Margins
-10,424.65%
Pretax Margin
-10,430.28%

Debt

Sales & Book Value

Annual Sales
$140,000.00
Book Value
($16.07) per share

Miscellaneous

Free Float
1,008,000
Market Cap
$11.96 million
Optionable
Not Optionable
Beta
1.18
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Joanne M. Hackett Ph.D. (Age 46)
    Interim CEO & Chairman of the Board
    Comp: $55.74k
  • Ms. Eun-Jae Park CPA (Age 52)
    Chief Financial Officer
    Comp: $295.29k
  • Dr. Ivan Labat
    Chief Information Officer
  • Ms. Judith Segall (Age 71)
    Secretary

AGE Stock Analysis - Frequently Asked Questions

When is AgeX Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our AGE earnings forecast
.

When did AgeX Therapeutics' stock split?

Shares of AgeX Therapeutics split before market open on Monday, March 18th 2024. The 8-5 split was announced on Monday, March 18th 2024. The newly issued shares were issued to shareholders after the closing bell on Monday, March 18th 2024. An investor that had 100 shares of stock prior to the split would have 160 shares after the split.

What other stocks do shareholders of AgeX Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AgeX Therapeutics investors own include Biocept (BIOC), Allena Pharmaceuticals (ALNA), Co-Diagnostics (CODX), Moleculin Biotech (MBRX), VBI Vaccines (VBIV), Arbutus Biopharma (ABUS), AIM ImmunoTech (AIM), AzurRx BioPharma (AZRX) and Digital Ally (DGLY).

Who are AgeX Therapeutics' major shareholders?

AgeX Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Sigma Planning Corp (0.75%).
View institutional ownership trends
.

How do I buy shares of AgeX Therapeutics?

Shares of AGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:AGE) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners